Understanding how GLP-1 medications affect abdominal fat distribution helps set realistic expectations for patients considering these therapies for weight management
The Kidney Disease: Improving Global Outcomes (KDIGO) organization provide a classification system for determining CKD risk based on cause , GFR , and albuminuria (Fig
Indications and Usage Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Important Safety Information for RYBELSUS WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
Resolves quickly with proper fluid intake but requires ongoing vigilance Serious But Less Common Side Effects The MHRA highlights several serious but less common risks that patients should know about 1 : Gallbladder problems: Including gallstones Pancreatitis: Inflammation of the pancreas, which can require hospitalization Allergic reactions: Can include swelling, rash, and trouble breathing Low blood sugar: Can happen even in non-diabetic patients using GLP-1s for weight loss Hair loss: Some patients report temporary thinning of hair Warnings About Misuse Healthcare professionals are concerned about people using GLP-1 medications inappropriately just for cosmetic weight loss
